WHERE THE DIFFERENCE LIVES
Sourcing, verification, documentation, storage, handling, labeling, and fulfillment vary substantially across suppliers, especially in the research-use-only (RUO) market. RUO peptides are sold and labeled for laboratory research, not as FDA-approved peptides. They sit in a different regulatory category from prescription medicines like Wegovy and Mounjaro, and the trust signal comes from the manufacturing chain (purity testing, batch documentation, lab verification) rather than from an FDA-approval stamp.
Two vials labeled "semaglutide" can come from very different supply chains with very different verification standards.
WHAT THE FDA HAS FLAGGED
The FDA has published specific concerns about unapproved GLP-1 products: dosing errors, fraudulent products, mismatches in the form of the molecule (the salt form, where different chemical pairings of the active ingredient with a stabilizer affect both the dose math and the stability), labeling problems, and quality-control gaps.
The molecule's name on the vial doesn't carry information about any of those.
What this means
"Same compound, same risk" collapses the supply system into the molecule. That is the wrong frame. Evaluating a peptide source means evaluating a chain of decisions, not a single chemistry result.
The molecule is the easy part. The system around the molecule is where the real difference lives.